FOXC1 and cancer: In the case of ovarian cancer, a retrospective study (133) demonstrated that positive immunostaining for FOXC1 protein significantly decreased with advancing International Federation of Gynecology and Obstetrics Stage (I-II vs. III-IV) as well as pathologic subtypes from benign to borderline and malignant tumors trending towards good prognosis.